Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.16 CAD | -1.82% | +2.37% | -20.00% |
04-17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
04-17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.00% | 113M | |
+39.73% | 54.04B | |
+44.47% | 41.96B | |
-1.49% | 41.92B | |
-7.20% | 28.35B | |
+12.44% | 26.35B | |
-21.82% | 19B | |
+7.19% | 13B | |
+29.52% | 12.28B | |
+25.59% | 12.19B |
- Stock Market
- Equities
- NGEN Stock
- News NervGen Pharma Corp.
- NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer